RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗：最新进展及其作为结直肠癌新辅助、辅助和主要治疗的未来
英文原题：Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
查看英文原题
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗在结直肠癌（CRC）领域过去十年取得了巨大进展。免疫检查点抑制剂是一类免疫治疗药物，已被证明可显著改善错配修复缺陷（dMMR）CRC患者的预后。目前，它们已成为该CRC亚型标准治疗的一部分。因此，人们对免疫治疗在其他CRC亚型中的疗效和时机越来越感兴趣，包括局部晚期、转移性和微卫星稳定（MSS）CRC。在本综述中，我们旨在探讨CRC的三大类免疫治疗——免疫检查点抑制剂（ICIs）、过继细胞转移疗法（ACT）和肿瘤疫苗——并讨论每一类的最新进展和未来方向。
展开英文摘要原文
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subset of CRC.
Because of this, there has been a growing interest in the efficacy and timing of immunotherapy for other subsets of CRC, including locally advanced, metastatic, and microsatellite stable (MSS). In this review, we aim to examine the three main classes of immunotherapy for CRC-immune checkpoint inhibitors (ICIs), adoptive cell transfer therapy (ACT), and tumor vaccines-and discuss the most recent advances and future directions for each.
论文信息
- 作者
- Yu I、Dakwar A、Takabe K
- 单位
- Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.United States
- 文献类型
- 综述 · 美国 NIH 资助研究
- 期刊
- Cells2023 Jan 8
- 原文标识
- PubMed 36672193 · DOI 10.3390/cells12020258
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →